Brind.

Litigation in Europe and ongoing FDA review are impacting the market viability and stock performance of Merck KGaA and SamChunDang Pharm.

1 report, 1 independent Updated Jul 1

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

Merck KGaA SamChunDang Pharm FDA Europe

Keep exploring

The entities involved

Merck KGaA
German multinational science and technology company
- Keytruda received FDA approval for cancer treatment, involving Merck KGaA.Mon 17:33
- Merck KGaA acquired Schering-Plough in 2009.Sun 17:36
SamChunDang Pharm
South Korean pharmaceutical company

Nothing else this week.
FDA
- Mesoblast received FDA approval for a specific product on June 1st, led by CEO Silviu Itescu.11:13
- The FDA approved Tonix Pharmaceuticals' drug, Tonmya, for use in treating fibromyalgia.09:41
Europe
terrestrial continent located in north-western Eurasia
- NATO, Donald Trump, and Europe discussed Ukraine aid, with Trump demanding Europe fund US assistance.13:24
- NATO allies strengthened their support for Ukraine while far-right leaders distanced themselves from Donald Trump.13:24

Related events

Menarini Group and NewAmsterdam Pharma Company N.V. are collaborating on drug development, seeking marketing authorization in Europe through the EMA and EC process.Jul 24

Coverage

Newest first; wire copies grouped

Jul 1edaily.co.krKosdaq Bio Rally...Alteogen Soars on European Patent Win [K-bio Pulse]